Mankind Pharmaceuticals, a key player in acute therapies, has sharpened its focus on chronic therapy drugs (like anti-diabetics and cardiac) and is eyeing 50 per cent revenue from this segment in three years. In fact, it recently applied to drugs regulator Drugs Controller General of India (DCGI), seeking approval to start phase 1 human trials of its novel anti-diabetes drug, which has completed animal trials.

Source: https://www.business-standard.com/article/companies/mankind-pharma-eyes-50-revenue-from-chronic-therapy-drugs-in-3-years-121042000044_1.html